Tag Archives: venture capital

RESI JPM 2026 Investor Panels Announced 

16 Dec

Attendees voted with their RESI Cash alongside judges’ scores to determine this year’s winners.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the investor panelists for RESI JPM 2026, taking place January 12–13 during JPM Healthcare Week. Across two full days, RESI JPM will bring together active investors, strategic partners, and industry leaders for focused discussions on the funding environment, partnership strategies, and emerging opportunities across life sciences and healthcare. 

RESI investor panels are designed to provide founders and executives with direct insight from decision-makers who are actively deploying capital, forming partnerships, and shaping the future of the industry. Each panel features experienced investors and strategics sharing candid perspectives, followed by opportunities to continue conversations through RESI’s structured partnering platform. 

Investor Speakers on Day 1 (January 12)


Sharon Chan
Johnson & Johnson Innovation – JLABS Asia Pacific
Irene Cheong
A*STAR
Ansbert Gadicke
MPM BioImpact

Dushyant Pathak
Autobahn Labs
Andrew Krowne
Dolby Family Ventures
Robert Balfour
ALSA Ventures

Rick Berenson
Mass Medical Angels
Gunes Bozkurt
Beiersdorf
Jian Cao
Medtronic

Jeff Chu
Features Capital
Karen Chu
Harvest Integrated Research Organization (HiRO)
Rod Cotton
2Flo Ventures

Juan Cueva
Johnson & Johnson Innovation
Bettina Ernst
BERNINA BioInvest
Jack Florio
NuFund Venture Group

Nirdesh Gupta
Cedars-Sinai Technology Ventures
Karen Harris
Alzheimers Drug Discovery Foundation
Uplaksh Kumar
Foresite Capital

Ken Lin
ABIES Capital
Michael Loftus
PoC Capital
Brianna McDonald
Ecosystem Venture Group

Swati Mehta
25BIO
Ahmed Mousa
LAFANA
Mahesh Narayanan
Neuvation Ventures

Kenny Nova
Mid Atlantic Bio Angels
Jessica Owens
INITIATE Ventures
Jojo Platt
Corundum Neuroscience

Steven Saltzstein
FORCE Family Office
Garth Smith
Ontario Brain Institute
James Spann
Boyd Street Ventures

Jessica Tam
Baxter Healthcare
Lee Chuan Teck
Enterprise Singapore
Varun Turlapati
Chaanakya Capital 

Investor Speakers on Day 2 (January 13)


Friedemann Janus
Bayer
Jiaping Gu
Takeda Ventures
David Berry
Averin Capital

Ekaterine Kortkhonjia
Johnson & Johnson Innovation
Nick Naclerio
Illumina Ventures
Eric Schaefer
March of Dimes

Marc Appel
Pacific Bridge NY
Anjan Aralihalli
Raya Therapeutic
Yaron Daniely
aMoon Fund

Miriam Dong
ID3 Ventures
Cristina Escoda
Tachyon Ventures
Yinghong Gao
Viva BioInnovator

Gary Gershony
BayMed Venture Partners
Tom Gibbs
Debiopharm Innovation Fund
Rohit Jain
HBS Alumni Angels of Northern California

Sai Jasti
Bayer
Anula Jayasuriya
Kidron Capital
Gautam Kainth
TCP Health Ventures

Jin Lee
Oxonian Ventures
Brian Miglionico
Agios Pharmaceuticals
Ralph Morales III
Aquillius Ventures

Stephanie Oestreich
Myeloma Investment Fund
Donna Parr
Cross-Border Impact Ventures
Bibi Sattar Marques
Buenavista Equity Partners

Takehiko Sawabe
Beyond Next Ventures
Venkat Srinivasan
Innospark Ventures
Anthony Vallance-Owen
We Venture Capital

Chensu Wang
Yonjin Venture
Chris Yoo
Xcellerant Ventures
Qing Zhang
LDV Partners

Register for RESI JPM 2026 

RESI JPM 2026 offers more than panels. Attendees gain access to curated investor meetings through RESI’s partnering system, targeted networking, and programming designed to support meaningful connections during one of the most important weeks in healthcare investment. 

Register for RESI JPM 2026

Tags: , , , , , , , , , , , , , ,

Sunday Space + Two Full Days of RESI JPM

16 Dec

By Sougato Das, President and COO, LSN

Sougato-Das

RESI JPM 2026 expands the opportunity to connect by adding Sunday partnering and event space, giving attendees an early start to JPM Week. With RESI JPM running Monday–Tuesday, Sunday provides a strategic window to schedule investor meetings, host receptions, or bring teams together while momentum is already building across San Francisco.

RESI JPM is the only JPM conference where 700+ investors actively providing seed to Series B funding attend, alongside in-licensors seeking preclinical through Phase 2 assets. For preclinical and clinical-stage biotech, medtech, diagnostic, digital health, and AI companies, RESI JPM remains the most efficient way to connect with aligned investors and strategic partners during JPM Week. Many companies schedule 10–20 meetings in a single day, making partnering the core of the RESI experience.

New Sunday Partnering Opportunities Added

Life Science Nation is announcing additional partnering slots on Sunday, January 11, hosted at the Marriott Marquis. These meetings take place ahead of the main conference and allow attendees to secure valuable investor conversations before calendars fill up.

The Sunday Partnering Slot sign-up form is available to RESI attendees, allowing registered participants to request meetings and plan their schedules in advance.

Start JPM Week with Purpose

This added day gives companies a head start to:

  • Schedule investor or in-licensor meetings
  • Connect with fellow RESI attendees
  • Host private meetings or team gatherings

Located in the center of the JPM ecosystem, the Marriott Marquis offers a convenient and efficient setting to begin JPM Week with focused, high-value interactions.

With Sunday now in play, RESI JPM 2026 delivers more time, more access, and more opportunities to make meaningful connections before the week reaches full pace.

Register for RESI JPM 2026

Tags: , , , , , , , , , , , , , , , , , , ,

Innovator’s Pitch Challenge Winners Announced at RESI London 2025 

9 Dec

Attendees voted with their RESI Cash alongside judges’ scores to determine this year’s winners.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the winners of the Innovator’s Pitch Challenge (IPC) at RESI London 2025. This year’s competition featured 26 participating companies, each showcasing early-stage technologies to a panel of experienced investors and an audience of global attendees. 

The IPC remains a cornerstone of every RESI conference, allowing founders to present to a coordinated group of investors who provide interactive questions and valuable feedback. Attendees cast votes using their RESI Cash, which was combined with judges’ assessments to select this year’s top companies. 

Congratulations to the RESI London 2025 IPC winners: 

These companies stood out among a highly competitive group of innovators spanning therapeutics, medical devices, diagnostics, and digital health. 

Congratulations, as well, to the companies from each session who received the highest judges scores:  

Looking ahead: Applications are now open for Life Science Nation’s next European conference, taking place in Portugal on March 23, 2026. Companies interested in pitching can apply here. 

Apply to Pitch at RESI Europe

Tags: , , , , , , , , , , , ,

Why the world is looking to Brisbane, Australia for the future of health innovation

9 Dec

As Brisbane’s next wave of MedTech companies prepares to take the global stage at J.P. Morgan Healthcare Week in January 2026, the international investment community is paying closer attention to a city rapidly emerging as an Asia Pacific life sciences powerhouse. 

Brisbane’s A$201 billion economy is anchored by a A$22 billion health sector, fuelled by strong population growth and a purposeful pipeline of public and private investment.  

As Australia’s fastest-growing major city, Brisbane is being reshaped by an A$18 billion health infrastructure pipeline, creating the largest interconnected health precinct in the Southern Hemisphere, spanning hospitals, universities and innovation hubs. 

This momentum is translating directly into commercial strength. Brisbane’s health industry and export capability are expanding faster than anywhere else in Australia, supported by world-class research institutions such as The University of Queensland. 

Turning innovation into investment 

At the centre of this growth sits the MedTech Global Accelerator, delivered by Brisbane Economic Development Agency (BEDA) in partnership with Life Science Nation (LSN). The program prepares founders to launch a global funding campaign through commercial readiness and direct international investor engagement. 

Since launch, the accelerator has supported more than 30 high-potential companies to raise over A$336 million in capital. 

An additional 10 high-growth companies have now been selected for the 2026 cohort. Their technologies range from a blood test for early-stage ovarian cancer and a world-first artificial heart, to cancer-fighting compounds derived from Queensland rainforests, each with potential to transform global healthcare. 

Be part of Brisbane’s next global MedTech wave 

Collectively, these companies represent Brisbane’s next generation of globally scalable health technologies as they prepare to showcase to international investors in San Francisco in January 2026. 

MedTech Global Accelerator Cohort

BEDA offers investors and partners early access to these vetted innovators through its official MedTech Innovation Showcase Compendium. 

Join the Brisbane, Queensland Investor Innovation Showcase on Monday, 12 January 2026, 9am–12pm, at Marriott Marquis, in collaboration with Trade and Investment Queensland and LSN. 

Register for the Investor Innovation Showcase today. 

BEDA serves as one of the front doors to Australia’s rapidly expanding clinical trial ecosystem, connecting partners to Queensland’s world-class trial sites, hospitals, universities and research institutions. Through this statewide, highly networked framework, BEDA helps fast track access to clinical research capabilities from Phase I to Phase IV. 

Why global investors are watching Brisbane, Australia: 

  • 43.5% R&D tax incentive 
  • Clinical trials run up to 3x faster than USA, 2x faster than UK 
  • Variable payroll tax rates in Australia 
  • Closest export hub to Asia 
  • Fastest planning approval on Australia’s east coast 
  • Host of the 2032 Olympic & Paralympic Games 
  • Top 40 Innovation City worldwide 
  • Highest innovation hub density in Australia (140 per capita) 
  • Direct access to Asia Pacific markets 
  • Health sector projected to grow 36% by 2032 
  • Leading clinical trials: 160+ sites, 40 CROs statewide 

With world-class research, deep clinical capability and fast-growing commercial opportunities, Brisbane is positioning itself as one of the most compelling gateways to Asia Pacific health innovation, and a city where early investment could deliver significant global reach. 

BEDA CEO Anthony Ryan said Brisbane’s MedTech ecosystem has accelerated at remarkable pace. 

“Brisbane has grown up fast as a MedTech city,” Mr Ryan said.  

“Today, everything connects in one place, from research and hospitals through to manufacturing and global investors. That full pathway is what makes this such a powerful time to be building and investing here.” 

He said global attention is now firmly on Brisbane. “We are seeing serious interest from around the world,” he added. “The infrastructure is ready, the talent is here and the companies coming through our accelerator are built to compete globally.” 

Infrastructure driving faster translation 

Brisbane’s Inner-City Knowledge Corridor serves as the heart of the city’s research and development, linking together institutions involved in research, hospitals, clinical care, manufacturing, and commercial activities. 

Combined with Brisbane Airport, this corridor forms a “golden triangle,” connecting research and development to export opportunities and giving businesses access to the vast $90 trillion Asia Pacific market. 

Together, these assets enable companies to move from discovery to clinical validation and commercial manufacturing within a single urban corridor – accelerating collaboration, speed to market and global scalability. 

Learn more about the city’s key health infrastructure driving Brisbane’s biomedical ecosystem:  Health Innovation Infrastructure Showcase 

Tags: , , , , , , , , ,

You are Invited! Join Kansai Life Science Accelerator Program (KLSAP) Demo Day at RESI JPM 2026 

2 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Join us for a special showcase of Japan’s most promising early-stage life science innovators at the KLSAP 2025 Demo Day, presented by the Kobe Biomedical Innovation Cluster (KBIC). This dynamic session will feature three finalists from the Kansai Life Science Accelerator Program alongside eight KBIC startups and alumni. Companies will deliver focused pitches highlighting new advances in therapeutics, medical platforms, diagnostics, and digital health, followed by live Q&A with global investors.

Hosted during RESI JPM 2026, this session is an excellent opportunity for investors, BD teams, and innovation scouts looking to connect with high-potential Japanese technologies poised for global expansion.

📅 January 13, 12:00–2:00pm PST
📍 Golden Gate C3 Room, Marriott Marquis San Francisco

Agenda: 
12:00–12:03 Opening – KLSAP Overview

12:03–12:45 KLSAP 2025 Demo Day 
Featuring 3 Finalist Companies (7 minute pitch + 6 minute Q&A with investor panel) 

C-Biomex GeneMedicine ixgene

12:45–12:50 KLSAP 2025 Demo Day Closing – KBIC Introduction 

12:50–1:53 KBIC Startups and Alumni Speed Pitches 
Featuring 8 startups (5 minute pitch) 

aceRNA-Technologies Celaid CellFiber
CynosBio FerroptoCure linqmed
quadlytics

1:53–2:00 KBIC Session Closing 

RSVP to Attend

Tags: , , , , , , , , , , , ,

RESI JPM 2026 IPC Finalists 

2 Dec

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Life Science Nation is pleased to announce the finalists for the Innovator’s Pitch Challenge (IPC) at RESI JPM 2026. Taking place over two full days in San Francisco, RESI JPM will once again bring together early-stage life science and healthcare innovators with a global community of investors seeking opportunities across drugs, devices, diagnostics, and digital health (4Ds). 

This year’s IPC will run as a continuous track, with finalists presenting in dedicated sessions held every hour across both days of RESI JPM 2026. These startups will showcase technologies poised to address key challenges across the 4Ds and advance the next generation of healthcare innovation. 

The IPC gives founders a rare opportunity to pitch directly to active investors, including VCs, family offices, corporate venture groups, and angel networks. Presenting companies receive actionable feedback, participate in meaningful conversations with investors, and gain visibility among the hundreds of attendees in the RESI partnering community. 

Finalists will also present their technologies in the RESI Exhibition Hall, creating additional touchpoints for networking and ongoing discussion throughout the conference. 

About the RESI Innovator’s Pitch Challenge 

The IPC remains a defining element of all RESI conferences. Each pitch session brings together a coordinated panel of investors who deliver interactive, constructive feedback designed to help founders refine their fundraising narrative. IPC participants receive conference registration with full access to partnering, exhibit space in the RESI Exhibition Hall, and the opportunity to compete for a complimentary registration to a future RESI event. 

Join Us at RESI JPM 2026 

RESI JPM 2026 will feature a two-day, in-person experience in San Francisco, offering expanded opportunities for partnering, investor panels, workshops, networking, and an IPC track running every hour across both days. Full event details, including registration and program updates, can be found at the RESI Conference website. 

Meet the RESI JPM 2026 Innovator’s Pitch Challenge Finalists: 

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , , , , , ,

Explore the RESI London 2025 Program Guide 

25 Nov

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022The official program guide for RESI London 2025 is now available! Redefining Every Stage of Investment (RESI) is designed to connect life science and healthcare innovators with a global network of investors across diverse funding strategies, from Seed through Series B and beyond.

This guide provides a complete overview of what to expect throughout the conference, detailing the content and layout for our in-person event on December 4th. Inside, you’ll find the full agenda, speaker bios, panel descriptions, and essential information to help you navigate your RESI experience. Whether you’re participating in investor meetings, the Innovator’s Pitch Challenge, workshops, or ad hoc networking, this guide is your resource to stay organized and maximize your time at RESI London.

Access the full guide here:

Register for RESI London

Tags: , , , , , , ,

← Older Entries
Newer Entries →